

1,400+ patient studies show zero percent infection rate when using XPERIENCE™

Next Science Limited (ASX:NXS) (“Next Science” or “the Company”) today announces the release of preliminary results from two retrospective studies by Dr Ravi K. Bashyal, an orthopaedic surgeon based in Chicago, Illinois, which found XPERIENCE™ to be efficacious in preventing periprosthetic joint infection (PJI) in patients undergoing knee (TKA) and hip (THA) arthroplasties (joint replacement).

Next Science is a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health.

In a video posted on VuMedi¹, Dr Bashyal discusses the findings of several studies into the efficacy of Next Science’s advanced surgical irrigation product XPERIENCE™. The video can be accessed via the following link. <https://www.vumedi.com/video/0-infection-rate-in-over-1000-consecutive-thatka-utilizing-a-novel-irrigant/>

The key details of the retrospective infection studies, including expected timing of publication of study results, are set out below:

- 2022 Retrospective Post Operative Infection Rates** – A 1,295-patient study in which XPERIENCE™ was used exclusively in 471 consecutive knee and hip arthroplasties during the 2022 calendar year and the rate of Surgical Site Infection (SSI) was compared against a control group comprising 824 knee and hip arthroplasties performed during 2020 and 2021. The overall SSI rate in the 2022 471 patient cohort was zero percent (0 patients out of 471) compared to a 0.5% infection rate among the control group (4 patients out of 824). The paper outlining this study has been submitted and is expected to be published in the coming months.
- 2023 Retrospective Post Operative Infection Rates** – To test the results over a broader period, the 2022 study was repeated in calendar year 2023 with XPERIENCE™ used exclusively in 1,000 knee and hip arthroplasties performed in 2023 and compared against the same 2020 and 2021 control group. As of mid-March 2024, the rate of SSI in the 2023 patient group was again zero percent with the final patients for the 2023 year close to completing their 90-day outcomes. Data collection for this study was scheduled for completion at the end of March 2024 with publication expected later in the year.

Next Science’s CEO and Managing Director, I.V. Hall, said: “Next Science’s mission is to significantly improve patient outcomes and elevate physician efficacy. We are delighted that with the use of our XPERIENCE™ product, Dr Bashyal, a leading orthopaedic surgeon, has reduced to zero the rate of Surgical Site Infection amongst his patients up to 90 days post-surgery. As Dr Bashyal highlights, infection remains a principal driver of negative outcomes

¹ A video education platform for doctors

NEXT SCIENCE®

for patients and physicians, and XPERIENCE™ brings much needed innovation to this area of orthopaedics. These studies add to the growing body of clinical evidence that increasingly challenge the standard of care in surgical irrigation. We will continue to work closely with surgeons to conduct clinical research that demonstrates the effectiveness of our products.”

Approved and authorised for release by the Managing Director.

Media & Investor Enquiries

Françoise Dixon

Phone: +61 412 292 977

Email: fdixon@nextscience.com

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com

Forward looking statements

This announcement may contain forward looking statements which may be identified by words such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may” and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involved known and unknown risks uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management and could cause Next Science's actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.